Literature DB >> 28913827

When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection.

Kevin Klein1,2, Joep H G Scholl3, Marie L De Bruin1,4, Eugène P van Puijenbroek3,5, Hubert G M Leufkens1, Pieter Stolk1,2.   

Abstract

Concerns have been expressed that large numbers of nonvalue-added reports have been accumulating in adverse drug reaction (ADR) databases, for example, via patient support programs. We performed an assessment of the impact of such reports, which we refer to as "precautionary reports," on safety signal detection in the Netherlands. The case narratives of ADR reports of three case products were screened with text-mining algorithms to identify those reports that lack a causal relationship with the suspected medicinal product. We demonstrate that precautionary reports impede the optimal use of the pharmacovigilance system by, on the one hand, masking safety signals and, on the other hand, creating spurious signals. The precautionary reporting bias and its suppressing effect on statistical signal detection results in an altered adverse event safety profile. The findings from this study highlight the need for a better alignment between regulatory authorities and marketing authorization holders regarding pharmacovigilance guidelines.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28913827     DOI: 10.1002/cpt.879

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.

Authors:  Kathryn Marwitz; S Christopher Jones; Cindy M Kortepeter; Gerald J Dal Pan; Monica A Muñoz
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System.

Authors:  Monica A Muñoz; Gerald J Dal Pan
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

3.  Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.

Authors:  Lisa Harinstein; Dipti Kalra; Cindy M Kortepeter; Monica A Muñoz; Eileen Wu; Gerald J Dal Pan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

4.  Response to "Pharmacovigilance 2030: Invited Commentary for the January 2020 'Futures' Edition".

Authors:  Manfred Hauben; William W Gregory; Patrick Caubel
Journal:  Clin Pharmacol Ther       Date:  2020-03-20       Impact factor: 6.875

5.  Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance.

Authors:  Jeremy D Jokinen; Rosalind J Walley; Michael W Colopy; Thomas S Hilzinger; Peter Verdru
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

6.  Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.

Authors:  Peter Arlett
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

7.  The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.

Authors:  Kevin Klein; Lorna Hazell; Pieter Stolk; Saad Shakir
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.